IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0280442.html
   My bibliography  Save this article

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France

Author

Listed:
  • Loïg Gaugain
  • Hélène Cawston
  • Coline Dubois de Gennes
  • Javier Sanchez Alvares
  • Pierre Nahon
  • Benjamin Mazaleyrat
  • Clément Le Dissez

Abstract

Background and aims: The IMbrave150 clinical trial assessed the efficacy and safety of atezolizumab in combination with bevacizumab (ATZ+BVA) versus sorafenib in adults with advanced/unresectable hepatocellular carcinoma, who have not received prior systemic treatment. Our aim was to assess the cost-effectiveness of ATZ+BVA versus sorafenib in France based on an updated prices and considering French National real-world data, to confirm the initial recommendations from the Heath Technology Assessment submission published in 2021, and provide additional visibility to decision-makers reflecting current clinical practice. Methods: A partition survival model was developed to project clinical outcomes, quality of life, and costs of patients with HCC treated with ATZ+BVA versus sorafenib over a lifetime horizon. Survival outcomes were extrapolated via parametric functions for both treatment strategies. Quality of life (EQ-5D-5L, French tariffs) were sourced from IMbrave150. The Guyot method was considered as a scenario analysis by integrating retrospective real-world data extracted from the French Health Insurance Database to refine long term survival extrapolations. Results: In the reference case, ATZ+BVA was associated with 0.61 additional Quality Adjusted Life Years (QALYs) compared to sorafenib (1.95 vs 1.35), and an incremental cost of €92,704. The incremental cost-utility ratio (ICUR) was 152,974 €/QALY gained. Adjusting the survival curves with French external evidence led to a 14% ICUR reduction (131,163 €/QALY). Conclusions: ATZ+BVA is a cost-effective strategy based on the range recently published for the value of a QALY in France and offers better chances of survival to patients.

Suggested Citation

  • Loïg Gaugain & Hélène Cawston & Coline Dubois de Gennes & Javier Sanchez Alvares & Pierre Nahon & Benjamin Mazaleyrat & Clément Le Dissez, 2023. "Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France," PLOS ONE, Public Library of Science, vol. 18(1), pages 1-12, January.
    • Handle: RePEc:plo:pone00:0280442
    DOI: 10.1371/journal.pone.0280442
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0280442
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0280442&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0280442?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Patricia Guyot & Anthony E. Ades & Matthew Beasley & Béranger Lueza & Jean-Pierre Pignon & Nicky J. Welton, 2017. "Extrapolation of Survival Curves from Cancer Trials Using External Information," Medical Decision Making, , vol. 37(4), pages 353-366, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Taihang Shao & Mingye Zhao & Leyi Liang & Lizheng Shi & Wenxi Tang, 2023. "Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067," PharmacoEconomics - Open, Springer, vol. 7(3), pages 383-392, May.
    2. M. Campioni & I. Agirrezabal & R. Hajek & J. Minarik & L. Pour & I. Spicka & S. Gonzalez-McQuire & P. Jandova & V. Maisnar, 2020. "Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(2), pages 219-233, March.
    3. Daniel Gallacher & Peter Kimani & Nigel Stallard, 2022. "Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations," PharmacoEconomics, Springer, vol. 40(1), pages 109-120, January.
    4. Nicholas R. Latimer & Kurt Taylor & Anthony J. Hatswell & Sophia Ho & Gabriel Okorogheye & Clara Chen & Inkyu Kim & John Borrill & David Bertwistle, 2024. "An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?," PharmacoEconomics, Springer, vol. 42(12), pages 1395-1412, December.
    5. Zhaojing Che & Nathan Green & Gianluca Baio, 2023. "Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trials in Health Technology Assessment," Medical Decision Making, , vol. 43(3), pages 299-310, April.
    6. Ash Bullement & Mark Edmondson-Jones & Patricia Guyot & Nicky J. Welton & Gianluca Baio & Matthew Stevenson & Nicholas R. Latimer, 2024. "MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial," PharmacoEconomics, Springer, vol. 42(12), pages 1317-1327, December.
    7. Alexina J. Mason & Manuel Gomes & James Carpenter & Richard Grieve, 2021. "Flexible Bayesian longitudinal models for cost‐effectiveness analyses with informative missing data," Health Economics, John Wiley & Sons, Ltd., vol. 30(12), pages 3138-3158, December.
    8. Ash Bullement & Matthew D. Stevenson & Gianluca Baio & Gemma E. Shields & Nicholas R. Latimer, 2023. "A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment," Medical Decision Making, , vol. 43(5), pages 610-620, July.
    9. M. A. Chaudhary & M. Edmondson-Jones & G. Baio & E. Mackay & J. R. Penrod & D. J. Sharpe & G. Yates & S. Rafiq & K. Johannesen & M. K. Siddiqui & J. Vanderpuye-Orgle & A. Briggs, 2023. "Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up," Medical Decision Making, , vol. 43(1), pages 91-109, January.
    10. Kun Kim & Michael Sweeting & Nils Wilking & Linus Jönsson, 2024. "General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in Sweden," Medical Decision Making, , vol. 44(7), pages 843-853, October.
    11. Philip Cooney & Arthur White, 2023. "Direct Incorporation of Expert Opinion into Parametric Survival Models to Inform Survival Extrapolation," Medical Decision Making, , vol. 43(3), pages 325-336, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0280442. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.